

# ECNP

**EUROPEAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY**

**AND**

**ECNP RESEARCH AND SCHOLARSHIP FOUNDATION**

## **ANNUAL REPORT AND POLICY PLAN 2016**



# Contents

INTRODUCTION	3
GOVERNANCE	5
PROMOTING WORLD-CLASS RESEARCH	13
FOSTERING JUNIOR SCIENTISTS	20
ADVOCATING FOR THE FIELD	28
FINANCIAL REPORT	35



# Introduction

2016 was an outstanding year for ECNP. Our congress in Vienna was a significant success, with nearly 5,000 participants from 100 countries. The record number of session proposals and abstract submissions speaks to the congress's ever-increasing reputation as the premier forum for the world's best applied neuroscience. Our educational programmes included seven meetings in seven different countries, with some 300 junior scientists from over 20 European countries participating. Our Networks initiative grew to 13 Networks and provided the catalyst for several multi-million-euro European proposals, including the pioneering PRISM project. The Neuroscience-based Nomenclature project consolidated its position as a fundamental tool for the understanding of psychiatric medications. Our new Executive Committee was our most diverse, with the largest proportion of women ever.

The science we serve also continues to evolve in exciting new ways, with important advances being made across the front of brain research. The quality of the winners of the ECNP Neuropsychopharmacology Award is just one example of the vibrancy of the research base. New areas are also opening up, in e-health and big data, and new convergences forming. Some of this new science is being successfully converted into treatments, often by smaller, niche companies, and the commercial environment is changing accordingly.

These successes, however, conceal a disturbing paradox. For all these advances, the mainstay of treatment for neuropsychiatric disorders continues to be medicines, and the development of new medicines is not keeping pace. The reasons for this are multifaceted and complicated, but their effect has been the scaling-back by many of the field's traditional industry leaders of their CNS operations, with some exiting entirely. This resulting withdrawal of investment has triggered knock-on effects throughout European neuroscience, and ECNP has seen the consequences both in the numbers of junior scientists not finding jobs and in lower participation in the ECNP Congress. This at a time too when the best estimates suggest that every year as many as one in three Europeans suffers from a mental disorder.<sup>1</sup> The need for effective treatments is, if anything, getting greater.

## THE MAGNITUDE OF THE CHALLENGE<sup>1</sup>

- Every year 38.2% of the EU population – 164.8 million people – suffers from a mental disorder
- 72.2% of mood disorders and 54.3% of all anxiety disorders are comorbid
- Among all 12-month cases with mental disorders only 2-9% receives minimally adequate treatment – the majority receives no treatment at all

<sup>1</sup>From the benchmark ECNP-funded longitudinal study, 'The size and burden of mental disorders and other disorders of the brain in Europe 2010,' H.U. Wittchen et al., *European Neuropsychopharmacology*(2011) 21, 655–679.

Responding to this twofold challenge – of a blockage in the development of new medications and the generally worsening economic environment in CNS – defines ECNP’s strategy. On the economic side, it has forced us to make certain rationalisations in preparation for what is likely to be increasingly heavy weather going forward. This means both reviewing ECNP’s cost structure to maximise efficiencies and re-fixing our focus onto core priorities.


ECNP operates a unique piece of the European research infrastructure and is fortunate enough to be unusually well resourced by the standards of what is a relatively under-funded disease area. The organisation is highly aware of the responsibilities these conditions entail. ECNP’s mission is more relevant now than ever.

The following report provides an overview of how ECNP is executing against that mission, and responding to this environment. None of it would be possible without the voluntary input of time and energy of hundreds of scientists. We have tried where possible to give due acknowledgement, but inevitably the limitations of space mean many more must go unnamed. We are acutely conscious of their contributions, however. As long as ECNP continues to enjoy this extraordinary level of commitment, the organisation will thrive.

Celso Arango  
President



Alexander Schubert  
Executive Director



# Governance

ECNP was founded in 1987 to advance the science of treatments for disorders of the brain. That remit continues to be at the heart of all of the organisation's activities. The principles behind this mission remain equally central: excellent science, rigorous governance, and commitment at all times and in every way to the larger public good.

## OUR OBJECTIVES

- Co-ordinating and promoting scientific activities and consistently high-quality standards between countries in Europe.
- Bringing together all those involved or interested in the scientific study of applied and translational neuroscience by arranging scientific meetings, seminars, and study groups.
- Providing guidance and information to the public on matters relevant to the field.
- Providing a format for the co-ordination and for development of common standards in Europe.

## OUR MISSION

*“To advance the science of the brain, promote better treatment, and enhance brain health.”*



## MANAGEMENT AND STRATEGY

The ECNP foundations, while legally independent and financially separate, are strategically and economically integrated, to the extent that the overarching goals and priorities are aligned. For the sake of convenience, the collective entity is hereafter called 'ECNP' or 'the College'.

The core goals of the College are:

- **Promoting world-class research**

Science is at the heart of ECNP's mission, and the College's role in helping to build and sustain the infrastructure by which outstanding research is generated and shared is the cornerstone of all of its activities. In order to keep its position at the forefront of research into the treatment of central nervous system disorders, ECNP continues to widen its scope from the classical pharmacology that were its roots to encompass all types of neuropsychiatric intervention. The 'neuroscience applied' by-line that functions as ECNP's motto is also its manifesto.

- **Fostering junior scientists**

ECNP remains highly committed to supporting junior scientists and clinicians in applied and translational neuroscience. This involves helping to develop the careers of especially promising juniors, as well as working to build the field and expand the range of career possibilities for juniors generally. Over half of ECNP's total budget is committed to this goal.

- **Advocating for the field**

Ensuring that the voice of high-quality science is heard in the public domain is becoming ever more important for organisations operating in the complex and sometimes contentious area of brain research and mental health, and ECNP takes this challenge very seriously. Although it remains an 'upstream' scientific society, the College is taking increasing steps to engage with patients, policy-makers and the broader public.

## OPERATING STRUCTURE

ECNP operates as an amalgamation of different entities. These entities are administratively co-ordinated but legally autonomous.

A very important organising principle in this structure is the Dutch 'ANBI' construction. An ANBI (algemeen nut beogende instelling) is an organisation that is recognised by the Dutch tax authorities as serving the public interest. It comes with a variety of compliance requirements. Central to these are that 90% of expenditure is committed to public good activities, that there is no profit motive, and that directors and policy-makers serve in an unpaid capacity.

### ECNP Association

The core constituent of the College is ECNP the member association, henceforth for the sake of clarity 'ECNP Association'. This is the original ECNP entity, founded in 1987 and constituted as a Swiss veren. The Swiss veren is a provision in the Swiss civil code that provides a statutory framework for associations, non-governmental

organisations and even businesses. This is the entity to which ECNP members belong. It is governed by the General Assembly and managed by the ECNP Executive Committee. Permanently established in the Netherlands and with its own endowment, the ECNP Association is registered as a public-interest-serving organisation (ANBI) under Dutch tax law.

## EXECUTIVE COMMITTEE – 2013-2016

Guy Goodwin, United Kingdom, *President*

Celso Arango, Spain, *President-elect*

Gitte Knudsen, Denmark, *Vice-president*

Joseph Zohar, Israel, *Past-president*

Mark Millan, France, *Secretary*

Eduard Vieta, Spain, *Treasurer*

### *Councillors*

Shijit Kapur, United Kingdom

Andreas Meyer-Lindenberg, Germany

Per Svenningsson, Sweden

Martien Kas, Netherlands

Laurance Lanfumey, France

Gil Zalsman, Israel

### *Non-voting Members*

Wim van den Brink, Netherlands, *Chair Scientific Programme Committee 26<sup>th</sup>, 27<sup>th</sup>, 28<sup>th</sup> ECNP Congress*

Joop van Gerven, Netherlands, *Co-opt Member*

Astrid Linthorst, United Kingdom, *Chair Scientific Programme Committee 29<sup>th</sup>, 30<sup>th</sup>, 31<sup>st</sup> ECNP Congress*

Andreas Meyer-Lindenberg, Germany, *Editor-in-Chief European Neuropsychopharmacology*

### *Executive Director*

Alexander Schubert, Netherlands



## EXECUTIVE COMMITTEE – 2016-2019

Celso Arango, Spain, *President*

Gitte Moos Knudsen, Denmark, *President-elect*

Laurence Lanfumey, France, *Vice-president*

Guy Goodwin, United Kingdom, *Past-president*

Martien Kas, Netherlands, *Secretary*

Eduard Vieta, Spain, *Treasurer*

### *Councillors*

Elisabeth Binder, Germany,

Damiaan Denys, Netherlands

Suzanne Dickson, Sweden

Catherine Harmer, UK

Stefano Pallanti, Italy

Gil Zalsman, Israel

### *Non-voting Members*

Gerry Dawson, United Kingdom, *Co-opt Member*

Joop van Gerven, Netherlands, *Co-opt Member*

Astrid Linthorst, United Kingdom, *Chair Scientific Programme Committee 29<sup>th</sup>, 30<sup>th</sup>, 31<sup>st</sup> ECNP Congress*

Andreas Meyer-Lindenberg, Germany, *Editor-in-Chief European Neuropsychopharmacology*

Mark J. Millan, France, *Co-opt Member*

Andreas Reif, Germany, *Chair Scientific Programme Committee 32<sup>nd</sup>, 33<sup>rd</sup>, 34<sup>th</sup> ECNP Congress*

### *Executive Director*

Alexander Schubert, Netherlands

## 2016 NOMINATING COMMITTEE

Joseph Zohar, Israel, *Chair*

Celso Arango, Spain

Nicoletta Brunello, Italy

Bill Deakin, United Kingdom

Guy Goodwin, United Kingdom

René Kahn, Netherlands

Marion Leboyer, France



## Stichting Buro ECNP

The Stichting Buro is a Dutch foundation established in 1993 to provide a framework under Dutch labour law for the recruitment of permanent personnel. It is the legal basis of the ECNP Office. It is managed by the Executive Director and overseen by its own two-member board.

## ECNP Research and Scholarship Foundation

ECNP Research and Scholarship Foundation (R&S) was founded in 1995 in order to provide a legal framework for ECNP's fundraising activities – essentially the ECNP Congress – under Dutch law. R&S is managed by a three-person board and has its own endowment. It is registered as an ANBI under Dutch tax law.

### R&S BOARD 2013-2016

Guy Goodwin, United Kingdom, *Chair*

Celso Arango, Spain, *Secretary*

Eduard Vieta, Spain, *Treasurer*

### R&S BOARD 2016-2019

Celso Arango, Spain, *Chair*

Gitte Moos Knudsen, Denmark, *Secretary*

Eduard Vieta, Spain, *Treasurer*

## The ECNP Congress Foundations

Every ECNP Congress is constituted as a stand-alone foundation, with its own three-person board. This procedure was begun in 1996 both to mitigate risk and to give explicit legal form to the congress's scientific, non-profit nature. Even though every ECNP Congress is of a non-profit nature, in the case that a congress does generate a net surplus, this surplus is disbursed in its entirety to R&S. Congress foundations are typically established two years before the congress in question and dissolved the year following. Each congress is registered as an ANBI under Dutch tax law.

### BOARD OF THE 29<sup>TH</sup> ECNP CONGRESS FOUNDATION

Guy Goodwin, United Kingdom, *Chair*

Celso Arango, Spain, *Secretary*

Eduard Vieta, Spain, *Treasurer*

For the annual reports of the ECNP Congress foundations, please visit the ECNP website.

## MEMBERS

ECNP association is a member organisation, and membership and volunteerism are central to the ECNP culture and mission.

Membership is open to all scientists and clinicians in relevant disciplines, and comes with a variety of benefits, almost all, however, non-material in nature. These include, above all, the chance to participate in ECNP's Europe-wide network of applied neuroscientists, including the ECNP Networks, to propose a Brainstorming Session at the ECNP Congress, to vote (Ordinary Members only) at the General Assembly, and to serve on an ECNP committee and help shape ECNP's future. Tangible benefits include reduced registration fees for the ECNP Congress and free subscription to the ECNP journal *European Neuropsychopharmacology*.

2016 saw the launch of a project to re-evaluate the member value proposition and develop new ways to enhance the member experience and build member numbers. This began with a survey of members in December, to which 197 members responded (28%), 78% of whom recorded feeling 'very connected' or 'fairly connected' to the organisation. Follow-up interviews for more qualitative detail are planned.

### ECNP MEMBERSHIP COMMITTEE

Per Svenningsson, Sweden, *Chair*

Hamish McAllister-Williams, United Kingdom

Carmen Moreno, Spain

Florian Riese, Switzerland

Eugenia Sinita, Moldova

#### MEMBERSHIP NUMBERS 31 DECEMBER 2016

Ordinary Membership	403
Ordinary Membership CDE	46
Associate Membership	58
Associate Membership CDE	57
Corresponding Membership	60
Corresponding Membership CDE	9
Emeritus Membership	18
Honorary Membership	7
Fellow Membership	61
Fellow Membership CDE	3
<b>TOTAL</b>	<b>721</b>

#### TOP 10 MEMBER COUNTRIES

1. United Kingdom
2. The Netherlands
3. Germany
4. Italy
5. Spain
6. France
7. USA
8. Sweden
9. Switzerland
10. Israel

## ECNP OFFICE

Based in Utrecht, the Netherlands, the ECNP Office is charged with the day-to-day management of all ECNP activities and the administration of its funds and resources. The Office finished 2016 with 10.3 full-time equivalent employees, under the management of the Executive Director.

### ECNP OFFICE

Alexander Schubert, *Executive Director*

Iris Allebrandi, *Director Congresses & Meetings*

Ellen van den Berg, *Director Operations*

Ligia Bohn, *Senior Project Manager Communication*

Godielieve Escartín, *Senior Project Manager Congresses & Meetings*

Corine ten Brink, *Project Manager Science & Education*

Eline Dimmendaal, *Project Manager Congresses & Meetings*

Annemieke Heuvink, *Project Manager Strategic Projects*

Petra Hoogendoorn, *Project Manager Science, Education & Communication*

Jolijn van Middelkoop, *Project Manager Congresses & Meetings*

Melinda Spitzer, *Project Manager Congresses & Meetings*

Wendy Schouten, *Assistant Project Manager Science and Education*



### KEY IDENTIFICATION NUMBERS

#### ECNP ASSOCIATION

VAT number: NL823523974B01

RSIN: 823523974

#### R&S

VAT number: NL807967087B01

RSIN: 807967087

Chamber of Commerce number: 41215196



The various projects and initiatives mentioned in this report fall under either the ECNP Association or R&S.

### ECNP ASSOCIATION PROJECTS AND INITIATIVES

European Neuropsychopharmacology  
ECNP Certificate  
ECNP Ambassadors  
ECNP Neuropsychopharmacology Award  
Medicine's Chest  
Communication  
European Affairs  
ECNP Brain Day



### R&S PROJECTS AND INITIATIVES

ECNP Workshop Neuropsychopharmacology  
ECNP Workshop on Clinical Research Methods  
ECNP School of Neuropsychopharmacology  
ECNP School on Child and Adolescent Neuropsychopharmacology  
ECNP Internship Programme  
ECNP Seminars  
ECNP Supported Talks  
ECNP Networks  
Brain Prize Master Class  
Innovation Meeting  
Neuroscience-based Nomenclature (NbN)  
Clinical Trails Platform  
Expert Platform on Mental Health – Focus on Depression (EPD)

# Promoting World-class Research

## THE ECNP CONGRESS

### *Europe's largest meeting in applied and translational neuroscience*

The 29<sup>th</sup> ECNP Congress was held on 17-20 September 2016 in Vienna, Austria. It featured 240 speakers; 66 sessions, including 35 scientific symposia, six plenary lectures, seven Educational Update Sessions, four Top Paper Sessions, nine Brainstorming Sessions, three Career Development Sessions, the patient session and the keynote lecture; seven satellite symposia; two Expert Science Exchanges; and 4,869 participants from 95 countries. 1,412 poster abstracts were submitted, of which 1,169 were accepted for presentation and 1,045 published.

Although the general downturn in neuroscience investment – especially in the industrial sphere – continues to press on congress numbers, total participation remained broadly consistent with 2015 (4,720) and 2015 (5,113). What is changing, however, is that the proportion of individual registrants is rising, along with the proportion that registration income constitutes of the congress's total receipts. These are clear, longer-term trends which are significantly altering the economics of the event, and we expect to see in future more break-even or even loss-making congresses.

Scientifically, however, the meeting continues to strengthen, as the rejection rate for scientific sessions (65%) and delegate participation rate (92%) aptly demonstrate. The scientific programme committee is working hard to enrich the content and extend its reach. This year's highly successful Top Paper Sessions and Expert Science Exchanges, both designed to provide new avenues of engagement, were fruits of this ongoing effort.

ECNP's commitment to helping less advantaged researchers and clinicians to attend the congress and benefit from its scientific opportunities is undimmed. This year, as well as more than 700 free registrations, € 90,000 was given in travel awards and subsidies to junior scientists and CDE<sup>2</sup> participants.



<sup>2</sup> I.e. nationals of a country with a developing economy. ECNP recognises 147 CDE countries round the world.

## AWARDS AND SUBSIDIES

- 443 free registrations for junior scientist poster presenters
- 270 free registrations for CDE poster presenters
- 14 Seminar Awards of € 1,000 each to selected ECNP Seminar participants
- 50 Travel Awards of € 500 each for outstanding junior scientist poster abstracts
- 9 Poster Awards of € 500 each for outstanding posters
- 93 CDE Grants of € 500 each for exceptional CDE abstract submitters

## SCIENTIFIC PROGRAMME COMMITTEE

Astrid C.E. Linthorst, United Kingdom, *Chair*

David Baldwin, United Kingdom

Catherine Belzung, France

István Bitter, Hungary

Katharina Domschke, Germany

Anne Eckert, Switzerland

David P. Finn, Ireland

Erkki T. Isometsä, Finland

Martien Kas, Netherlands

Laurence Lanfumey, France

Anne Lingford-Hughes, United Kingdom

Andreas Meyer-Lindenberg, Germany

Mara Parellada, Spain

Juha Rinne, Finland

Wim van den Brink, Netherlands

Krzysztof Wedzony, Poland

Gil Zalsman, Israel



## EUROPEAN NEUROPSYCHOPHARMACOLOGY

### *A world-class forum for published research*

*European Neuropsychopharmacology* is the official journal of the European College of Neuropsychopharmacology. One of the leading scientific journals in the field of applied and translational neuroscience, it features basic and clinical research from around the world. Covering the effects of centrally acting agents in its broadest sense, it is focused above all on translation. All ECNP members get online access to the journal, and have the possibility to order the print version.

In 2016 the Impact Factor of the journal increased to 4.409, which is a testament to the ever increasing popularity of the journal.


Thomson Reuters lists the journals in the following four categories:

- Clinical Neurology (European Neuropsychopharmacology is in the top 20% of 192 journals)
- Neurosciences (in top 25% of 256 journals)
- Pharmacology & Pharmacy (in top 15% of 253 journals)
- Psychiatry (in top 10% of 276 journals)

Total Science Direct  
downloads in 2016:  
**469,227**

476 manuscript submissions  
151 accepted for publication  
67.3% rejection rate

The most popular article in 2016 was downloaded 12,850 times





## EUROPEAN NEUROPSYCHOPHARMACOLOGY EDITORIAL BOARD

Andreas Meyer-Lindenberg, Germany, *Editor-in-Chief*

### *Associate Editors*

Michael Davidson, Israel

Jaanus Harro, Estonia

Rafael Maldonado, Spain

Brian Morris, United Kingdom

Andreas Reif, Germany

Thomas G. Schulze, Germany

Eduard Vieta, Spain

### *Editorial Board*

Schahram Akbarian, USA

Ravi Anand, Switzerland

Ian Anderson, United Kingdom

Celso Arango, Spain

Gyorgy Bagdy, Hungary

Dusan Bartsch, Germany

Michal Beeri, USA

Christoph U. Correll, USA

Filippo Drago, Italy

Veronique Fabre, France

Gabriele Fischer, Austria

D. Goff, USA

Vahram Haroutunian, USA

Shitij Kapur, United Kingdom

John H. Krystal, USA

Rupert Lanzenberger, Austria

Stefan Leucht, Germany

Stephen Levine, Israel

Andrea Malizia, United Kingdom

Philip McGuire, United Kingdom

Mark J. Millan, France

Karoly Mirnics, USA

Boris Quednow, Switzerland

R. Rabinowitz, Israel

Abraham Reichenberg, United Kingdom

David Rubinow, USA

Dan Rujescu, Germany

Trevor Sharp, United Kingdom

Karla Soares-Weiser, United Kingdom

Nicholas Stefanis, Greece

Abraham Weizman, Israel

Aysegül Yildiz, Turkey

Andreas Zimmer, Germany



## ECNP NETWORKS

### *Building pan-European research platforms*

The ECNP Networks were launched in 2007 to address the lack in Europe's research infrastructure of common Europe-wide databases for studies of psychiatric conditions. A decade later, the co-operation that the Networks have fostered is delivering significant research and public health benefits, not only providing essential variables for clinical analysis, but a springboard for European consortia of highly qualified investigators and platforms for collaborative projects.

In 2016 the programme was extended to 13 Networks, with the addition of the Nutrition Network. Total membership of the programme runs to over 300 of Europe's top applied neuroscience researchers.

The Experimental Medicines Network was also the catalyst for the € 16.6-million Innovative Medicines Initiative (IMI) project PRISM (Psychiatric Ratings using Intermediate Stratified Markers). Led by ECNP secretary Martien Kas, the project aims to develop quantitative biological measures for social and cognitive deficits in Alzheimer's disease, schizophrenia and major depression, which can be used for the discovery and development of new treatments. Several other major proposals to which the Networks have also given rise are in process. A networking meeting was held at the Vienna congress (19 September 2016) with Network leaders and representatives of industry to stimulate further collaborative bids.

The change of Executive Committee this year saw Celso Arango, Spain, replaced by Gitte Moos Knudsen, Denmark, as chair of the Networks board. Nic van der Wee, Netherlands, continues his essential work as scientific co-ordinator.

### ECNP NETWORKS AND MEMBERS OF THE NETWORKS TASKFORCE

**ADHD** Barbara Franke, Netherlands; Andreas Reif, Germany

**Anxiety Disorders (ADRN)** Borwin Bandelow, United Kingdom; Katharina Domschke, Germany

**Bipolar Disorders (ENBREC)** Michael Bauer, Germany; Lars Kessing, Germany; Ole Andreassen, Norway

**Child and Adolescent Neuropsychopharmacology** Alessandro Zuddas, Italy; Carmen Moreno, Spain

**Down Syndrome and Other Genetic Development Disorders** Marie-Claude Potier, France; Mara Dierssen, Spain

**Experimental Medicines** David Nutt, United Kingdom; Gerry Dawson, United Kingdom

**Neuroimaging** Peter Falkai, Germany; Hilleke Hulshoff Pol, Netherlands

**Nutrition** Suzanne Dickson, Sweden; Roger Adan, Netherlands

**Obsessive Compulsive and Related Disorders (OCRN)** Naomi Fineberg, United Kingdom; Dick Veltman, Netherlands

**Preclinical Data Forum** Anton Bernalov, Germany; Thomas Steckler, Belgium

**Schizophrenia** Silvana Galderisi, Italy; Dieter Naber, Germany

**Suicide** Danuta Wasserman, Sweden; Vladimir Carli, Sweden

**Traumatic Stress** Eric Vermetten, Netherlands; Joseph Zohar, Israel

## TARGETED NETWORK MEETINGS

### *Facilitating new collaborations*

The TNMs were launched to provide a platform for the Networks to access additional expertise and discuss strategies and unmet needs. Three TNMs were held in 2016, on 21 September in Vienna immediately after the ECNP Congress:

- ADHD Network – Hot topics in ADHD across the life span research
- Down Syndrome and Other Genetic Developmental Disorders Network – Common mechanisms and therapeutic avenues
- Bipolar Disorders Network – Technology and big data: perspectives in bipolar disorders

Outputs of the meeting will be presented at the 30<sup>th</sup> ECNP Congress in Paris. Organisational costs, including speaker expenses, are covered by the 29<sup>th</sup> ECNP Congress foundation; there is no registration fee.

## NEUROSCIENCE BASED NOMENCLATURE (NbN)



### *Leading the way in nomenclature reform*

This international collaboration, led by ECNP, aims to put the nomenclature of psychotropic drugs – long recognised as inadequate – on a scientifically sound pharmacological basis. By basing the new nomenclature on the latest neuroscience, the NbN seeks to help clinicians make informed choices when working out the next ‘pharmacological step’, to develop a system that can accommodate new types of compounds, and to enhance adherence by making the rationale for treatment choices clear to patients.

The NbN currently covers 108 compounds. 14 major international journals have adopted it as their reference nomenclature. 11 have published editorials on the system, with five more underway. The NbN smartphone app is approaching 15,000 downloads and has been expanded to include Japanese and Spanish versions, with Chinese, French and Portuguese editions planned. All the expenses related to the initiative have been met by R&S.

“We applaud the effort to develop a clearer nomenclature for psychopharmacology. We, the editors, are pleased that *Biological Psychiatry* and *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging* will participate in this initiative.”

John H. Krystal et al., *Biological Psychiatry* July 1, 2016; 80:2–3

## NbN TASKFORCE COMMITTEE

Joseph Zohar, Israel, *Chair* – ECNP

Pierre Blier, Canada – ACNP

Filippo Drago, Italy – IUPHR

Guy-Goodwin, United Kingdom – ECNP

David Kupfer, USA – ACNP

Hans-Jürgen Möller, Germany – CINP

David Nutt, United Kingdom – ECNP

Stephen Stahl, USA – CINP


Hiroyuki Uchida, Japan – AsCNP

Shigeto Yamawaki, Japan – AsCNP

## INNOVATION MEETING—'NEUROSCIENCE AND PSYCHOTHERAPY'

### *Pushing the frontiers of applied neuroscience*

Every March ECNP holds a two-day meeting in Nice, France, to explore some cutting-edge new development or emergent frontier in applied and translational neuroscience.



This year the meeting, held on 20-21 March, brought together neuroscientists, experimental psychologists and clinical psychologists to highlight a gap between neuroscience and practice in relation to talking treatments in psychiatry. The meeting, co-ordinated by Guy Goodwin and Emily Holmes, explored how evidence-based psychological treatments can benefit from the dramatic advances being made in neuroscience in relation to emotion, behaviour and cognition, and how neuroscience can benefit from the potential of psychological treatments, with the hope that experimental steps to establish how treatments work in man might open new possibilities for drug development.

The 80 participants illustrated the appeal and promise of psychological interventions, and the challenge translation continues to pose for those interested by drug treatments. As a result of the meeting, ECNP will in future provide a natural home for clinical psychologists who do translational neuroscience.

Outputs from the meeting were presented at a special session, 'From neuroscience to evidence based psychological treatments', at the 29<sup>th</sup> ECNP Congress in Vienna (20 September 2016).

Registration and all organisational costs, including speaker expenses, were met by R&S.

## ECNP NEUROPSYCHOPHARMACOLOGY AWARD



### *Rewarding outstanding achievement*

The ECNP Neuropsychopharmacology Award recognises innovative and distinguished research achievements in applied and translational neuroscience. The award is granted each year, alternating between basic science and clinical research, and is accompanied by a prize of €10,000, which the winner may share with junior collaborators.

The 2016 award was conferred upon John Geddes, UK, head of the Department of Psychiatry at Oxford University, for his exceptional research contributions to bipolar disorder and mood instability and their effects on clinical practice as well as scientific understanding. As joint recipients he selected Dr Jennifer Rendell and Dr Chris Hinds, also of Oxford University. John Geddes gave his award plenary lecture at the 29<sup>th</sup> ECNP Congress on 18 September 2016.



### 2016 ECNP AWARD COMMITTEE

Andreas Meyer-Lindenberg, Germany, *Chair*  
Anders Björklund, Sweden  
Will Carpenter, United States  
Paul Harrison, United Kingdom  
René Kahn, Netherlands



# Fostering Junior Scientists

The future of neuroscience depends on a steady supply of talented and highly skilled neuroscientists. This means not only high-quality training, but viable long-term career paths. One of ECNP's core priorities is to work towards ensuring both of these are available. A wide range of the College's initiatives and activities are dedicated to this end.

## ECNP EDUCATIONAL COMMITTEE

Gil Zalsman, Israel, *Chair*

Celso Arango, Spain

Avi Avital, Israel

Andrea Fagiolini, Italy

Naomi Fineberg, United Kingdom

Olga Kazakova, Belarus

Hamish McAllister-Williams, United Kingdom

Walter Pirker, Austria

Koen Schruers, Netherlands

## ECNP JUNIOR MEMBERS ADVISORY PANEL (JMAP)

Kfir Feffer, Israel, *Chair*

Nuno Dinis Alves, Portugal


Covadonga M. Díaz-Caneja, Spain

Marin Jukic, Sweden

Olga Kazakova, Belarus

Livia de Picker, Belgium

Joanna Slusarczyk, Poland



# ECNP WORKSHOP ON NEUROPSYCHOPHARMACOLOGY FOR JUNIOR SCIENTISTS IN EUROPE



## *Developing Europe's best young researchers*

Now in its twelfth year, the ECNP Workshop for Junior Scientists in Europe has become one of the most important educational events in the field. Held annually in Nice, France, the meeting provides three days of intensive education and interaction for 100 competitively selected junior scientists.

The 2016 ECNP Workshop was held on 17-20 March. 188 applicants vied for the 100 places. Eight speakers came from across Europe and North America.

Every Workshop focuses on three recurring topics and one variable topic, within each of which two distinguished scientists address specific themes, followed by short presentations of their research by five junior scientists. In addition to the three recurring topics – molecular and cellular, behavioural and systems and clinical and translational – this year's variable topic was 'The flip side of the brain, glia and their significance'. The keynote speaker was Mark J. Millan, France.

Sixteen junior scientists, selected on the basis of the quality of their posters, were invited to speak at two special sessions at the 29<sup>th</sup> ECNP Congress, on 18 and 19 September, in Vienna, Austria.

All organisational costs, including speaker expenses, are covered by R&S. For participating junior scientists, no registration fee is charged and travel and accommodation are almost entirely covered.

## ECNP WORKSHOP COMMITTEE

Mark J. Millan, France, *Chair*

Martien Kas, Netherlands, *Chair-elect*

William Deakin, United Kingdom

Suzanne L. Dickson, Sweden

Katharina Domschke, Germany

Philippe Fossati, France

Catherine Harmer, United Kingdom

Jaanus Harro, Estonia

Marin Jukic, Sweden


Astrid Linthorst, United Kingdom

Andreas Reif, Germany

David A. Slattery, Germany

Thomas Steckler, Belgium

Per Svenningsson, Sweden



## ECNP WORKSHOP ON CLINICAL RESEARCH METHODS



### *Inculcating essential research skills*

Launched in 2015, the ECNP Workshop on Clinical Research Methods introduces junior clinicians, including psychiatrists and clinical psychologists, to the techniques and methodologies of clinical research. The three-day workshop covers issues ranging from research in psychopharmacology and non-pharmacological research to how to read and write a scientific paper and start a successful scientific project and career.

Now in its second year, the 2016 Workshop was held on 4-6 November at the Hospital Clinic of the University of Barcelona, led by Eduard Vieta, Spain. This year numbers were increased from the 25 in 2015 to 31, almost a half from developing-economy countries.

All organisational costs, including speaker costs, were met by the ECNP Association. There was no registration fee. Hotel accommodation was provided by R&S.

“It gave me the opportunity to expand my views in clinical research and to learn about new achievements in this scientific area”

“An inspiring workshop fulfilling all the expectations of a junior scientist in his introduction into the clinical research world”

“A kind of workshop you would recommend to everyone that wants to start clinical research”

## ECNP SCHOOL OF NEUROPSYCHOPHARMACOLOGY



### *Teaching best practices to tomorrow's clinical leaders*

The ECNP Schools programme was designed as a clinically oriented complement to the highly successful ECNP Workshop formula.

Launched in 2009, the model was to provide a week-long residential programme of intensive training in all aspects of neuropsychopharmacology for exceptional young European clinicians. Participants are nominated by members of the ECNP Advisory Board of National Societies or ECNP Ambassadors, with two to three potential candidates per country, on the basis of their career potential. The course is designed to be propagated by participants on their return to their home countries.

The general School is held every summer in Oxford, England – this year on 26 June-1 July. Of the 157 applications, 50 were selected. The co-ordinator was Guy Goodwin, United Kingdom.

Organisational costs, including venue, speaker expenses and meals, are covered by R&S. Additionally, participant travel and accommodation costs were almost entirely covered by R&S.

## ECNP SCHOOL ON CHILD AND ADOLESCENT NEUROPSYCHOPHARMACOLOGY



### *Serving a vital need*

The ECNP School of Child and Adolescent Neuropsychopharmacology focuses on the use of medications, good clinical practice and optimal treatment strategies in paediatric psychopharmacology. Every year it offers a week-long residential programme of intensive training in Venice, Italy. This year the School was held on 3-8 April, with 50 participants selected from 135 applicants. The co-ordinator was Alessandro Zuddas, Italy.

The biennial ECNP School on Old Age Neuropsychopharmacology was, with regret, discontinued in 2016 due to what was felt to be the underdeveloped nature of the specialty in Europe and the insufficient demand.



## SEMINARS

### *Bringing the best science to developing European countries*

ECNP Seminar is an innovative format focused on providing promising young researchers and clinicians in a given developing-economy country an introduction to the key principles and currents in applied neuroscience.

The programme covers two days and provides interactive training in a concentrated learning environment with local and international experts. Up to 50 participants attend, selected on the basis of their curriculum vitae and a short abstract.

Two participants from each Seminar are awarded free registration and a subsidy towards travel costs for the succeeding ECNP Congress.

R&S covers all costs, including venue, meals and speaker expenses; participants are asked only to pay their own in-country travel expenses.

In 2016 there were four Seminars: in Serbia, Estonia, Hungary and Turkey.



#### **Vrdnik, Serbia, 22-24 April 2016**

43 people applied for the seminar and 39 participants were accepted to attend the seminar led by Celso Arango, Spain.

*Local co-ordinator:* Nadja Maric Bojovic

*Speakers:* Celso Arango, Spain; Philip K. McGuire, United Kingdom; Alan Apter, Israel

*Award winners:* Bojan Batinic, Marina Mihaljevic and Jelena Petrovic

#### **Vihula, Estonia, 20-22 May 2016**

34 people applied for the Seminar and 22 participants were accepted to attend the seminar led by Avi Avital, Israel.

*Local co-ordinator:* Eduard Maron, Estonia

*Speakers:* Avi Avital, Israel; Vladimir Carli, Sweden; Gal Shoval, Israel

*Award winners:* Kristi Krebs, Taavi Vanaveski and Liina Pappa



### Budapest, Hungary, 7-9 October 2016

44 people applied for the seminar and 39 participants were accepted to attend the Seminar led by Gil Zalsman, Israel.

*Local co-ordinator:* Xenia Gonda, Hungary

*Speakers:* Gil Zalsman, Israel; Avi Avital, Israel; Andrea Murru, Spain

*Award winners:* Biborka Bruzsik, Christina Miskolczy and Peter Ujma

### Ankara, Turkey, 21-23 October 2016

37 people applied for the Seminar and all were accepted to attend the seminar led by Avi Avital, Israel.

*Local co-ordinator:* Oguz Karamustafalioglu, Turkey

*Speakers:* Avi Avital, Israel; Carla Torrent, Spain; Dina Popovic, Italy

*Award winner:* Helin Yilmaz





## ECNP INTERNSHIP PROGRAMME

### *Career-building European exchanges*

The ECNP Research Internship aims to provide short-term research internship opportunities for junior researchers, across the spectrum of applied and translational neuroscience. Applicants are invited to identify an ECNP Fellow in another country at whose institution they would benefit from a two-week exploratory visit. The hosting scientist is encouraged to establish a long-term relationship with the intern and teach a basic translational research method which he or she can use at home.



Launched in 2014 with 10 interns, the programme currently accepts 15 annually.

## BRAIN PRIZE MASTER CLASS

### *Cultivating outstanding junior scientists*

This collaboration between ECNP and the Lundbeck Foundation gather Europe's most talented junior researchers for a uniquely concentrated educational experience within the framework of translational neuroscience. The master class was intended to leverage the expertise of the Brain Prize Academy and supplement the Foundation's international outreach programme as well as the scientific and educational activities of ECNP.



20 participants from across Europe – recruited from attendees at prior ECNP junior scientist meetings – were selected based upon their motivation and scientific potential. They received free registration, accommodation, a travel subsidy, and all meals, paid for by ECNP and the Foundation.

The two-day meeting was co-chaired by Trevor Robbins, United Kingdom, and Joseph Zohar, Israel.



# Advocating for the Field

The complexity of brain science and brain disorders places an especial premium on explanation and communication. As one of the leading independent scientific organisations in the field, ECNP is keenly aware on the responsibility to support public discourse with high-quality, evidenced-based information.

## ECNP BRAIN DAY

### *Reaching out to the public*

The ECNP Brain Day concept was launched in Berlin in 2014. The idea was to hold a meeting, adjacent to the ECNP Congress, that would be open to the public and that would bring some of the science of the congress to a general audience.

A second Brain Day followed in 2015 to accompany the 28<sup>th</sup> ECNP Congress in Amsterdam. The concept proved so popular, it was extended for a fourth iteration at the 29<sup>th</sup> Congress in Vienna. Held at the Medizinische Universität Wien on 16 September, the day before the congress, it attracted some 200 people.

The meeting featured a series of presentations by leading Austrian researchers on key developments in brain science and their applications to common mental disorders, including, dementia, schizophrenia, bipolar disorder, and ADHD. Speakers included Siegfried Kasper, Austria, Chair, on depression and anxiety, Dietmar Winkler on dementia, Eva Meisenzahl on schizophrenia, Andreas Erfurt on bipolar disorder, and Luise Poustka on ADHD.

A special highlight was the presentation during the meeting of the Expert Platform Media Award to Austrian television personality and mental health campaigner Wolfram Pirchner by ECNP Past President Josef Zohar, Israel.



## EXPERT PLATFORM ON MENTAL HEALTH – FOCUS ON DEPRESSION (EPD)

### *Generating awareness*

The Expert Platform is an awareness-raising initiative, administered by ECNP, that aims to disseminate high-quality evidence-based science about depression, its impact, treatment, and prevention. In 2016 the decision was taken to establish an independent Expert Platform Foundation.



### EPD ADVISORY BOARD

Joseph Zohar, Israel, *Chair* – European College of Neuropsychopharmacology (ECNP)  
Yoram Cohen, Israel – Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe)  
Sarada Das, Belgium – Standing Committee of European Doctors (CPME)  
Frédéric Destrebecq, Belgium – European Brain Council (EBC)  
Luis Gálvez-Alcaraz, Spain – World Organisation of Family Doctors (WONCA)  
Jacques de Haller, Switzerland – Standing Committee of European Doctors (CPME)  
Martin Grosse Holtforth, Switzerland – International Federation for Psychotherapy (IFP)  
Cyril Höschl, Czech Republic – European Psychiatric Association (EPA)  
Aagje Ieven, Belgium – European Federation of Associations of Families of People with Mental Illness (EUFAMI)  
Karl Kuhn, Germany – European Network for Workplace Health Promotion (ENWHP)  
Amelia Mustapha, United Kingdom – European Depression Association (EDA)  
Nigel Olisa, Belgium – Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe)  
Evanthia Sakellari, Greece – European Psychiatric Nurses (Horatio)

Key EPD projects include:

### European Evidence-based Suicide Prevention Programme (EESPP)

An initiative to collect, codify and propagate best practices in suicide prevention and provide early warning tools.

- Its landmark paper on suicide prevention, ‘Suicide prevention strategies revisited: 10-year systematic review,’ was published in June 2016 in *Lancet Psychiatry*.<sup>3</sup>
- Findings were presented at 6<sup>th</sup> International Symposium on Suicide and Suicidal Behaviour in Oviedo, Spain, on September 2016; at the EU Compass Forum on Mental Health and Well-being in Luxembourg, 6-7 October 2016; and at the meeting of the European Interest Group in Mental Health, ‘Preventing suicide – the evidence and next steps’, hosted by MEPs Nessa Childers, Marian Harkin, Jean Lambert and Cristian-Silviu Buşoi, on 9 November 2016.

<sup>3</sup> Gil Zalsman et al., *Lancet Psychiatry*, July 2016 3.7: 646-659.

- National suicide prevention councils (NSPP) are being organised in co-operation with the European Commission and World Health Organization for roll-out in Europe, with a kick-off meeting in Vilnius, Lithuania, May 2016, including government officials, local experts, outside experts (Merike Sisask from Tallinn University, Estonia) and EPD representative (Joseph Zohar, Israel). A follow-up meeting took place in Estonia in June 2016. A second kick-off meeting was held in Budapest, Hungary, in September 2016, including two representatives of the Hungarian government, the president of the Hungarian Psychiatric Association, local experts, patient representatives and EPD representative (Joseph Zohar, Israel). Following this meeting, a pilot NSPP was started.

### The Cost of Depression in the Workplace

This research project aims to provide quantitative evidence for the cost of depression for employers in Europe and suggest practical measures to address this challenge.

- The first paper, 'Evaluating the economic impact of screening and treatment for depression in the workplace,' drawing upon data from 4.1 million German insurance records, was published in *European Neuropsychopharmacology* in March 2016.<sup>4</sup>
- A second study in collaboration with the European Group for the Study of Resistant Depression (GSRD), providing occupation-level insights into the treatment of depression, 'High occupational level is associated with poor response to treatment of depression,' was published in *European Neuropsychopharmacology* in May 2016.<sup>5</sup>
- The results, presented at the 29<sup>th</sup> ECNP Congress in Vienna, received extensive worldwide coverage, including articles (amongst many others) in the *Kurier* ('Spitzenjobs vermindern die Wirkung von Antidepressiva,' 20 September 2016), *ScienceDaily* ('High status job means you are less likely to respond to treatment for depression,' 20 September 2016), *Los Angeles Times* ('For those in posh jobs, depression may be harder to treat,' 21 September 2016), *New York Magazine* ('Depression is tougher to shake if you're the boss,' 28 September 2016) and *PsychiatryTimes* (featured in the 'Depression Research Update,' 5 October 2016).
- Together these studies will provide the basis of a series of practical recommendations for employers, especially those of small and medium-sized enterprises.

### DepNet Patient Information Website

This depression information site is designed to provide a comprehensive online resource about depression and its treatment options for patients and the people close to them. It has been specifically aimed at countries with a pressing lack of high-quality, evidence-based information.

The site has been launched in:

- Moldova ([www.depnet.org/ro](http://www.depnet.org/ro)) in May 2015.
- Hungary ([www.depnet.org/hu](http://www.depnet.org/hu)) in February 2016.
- Armenia ([www.depnet.org/hy](http://www.depnet.org/hy)) in June 2016.
- Bulgaria ([www.depnet.org/bg](http://www.depnet.org/bg)) September 2016.

<sup>4</sup>Sara Evans-Lacko et al., *European Neuropsychopharmacology*, June 2016 26.6: 1004-1013.

<sup>5</sup>Laura Mandelli et al., *European Neuropsychopharmacology*, August 2016 26.8: 1320-1326.

The uptake in each case has been significant. Over the last six months of 2016, DepNet was visited by over 5,000 people. Of these sessions, 20% were returning visitors.

### iFeel Depression App

The iFeel app is the Expert Platform's most ambitious project, and offers an important breakthrough in treatment options for depression sufferers, and a powerful model for e-health treatment delivery. The app works by identifying changes in behaviour that may signal the onset of a depressive episode. By analysing an individual's habits and movements via his or her smartphone usage, the app is able to detect deviations from normal behavioural patterns and send an alert to a designated 'trust buddy'. iFeel is the only tool of its kind not commercially driven, open to all users, free of charge, and not reliant upon self-reporting, and is (about to be) clinically validated.

- Initial development of the prototype has been completed with the beta version finalised on the Android platform.
- In April 2016 the iFeel website, <http://www.ifeel.care>, was launched, along with the iFeel explanatory video.
- In conjunction with the patient groups GAMIAN-Europe and EUFAMI, 600 patients are being recruited for a multinational one-year scientific randomised control trial planned for 2017, to refine the algorithm and validate the tool.

### Media Award

The Expert Platform Media Award aims to contribute to the destigmatisation of depression by recognising people and/or projects that challenge depression stereotypes and stigma, and add to a better understanding of and stimulate discussion about depression. The award carries a prize of € 1,000 and a commemorative statue. The 2016 recipients were

- Armenian television producer David Petrosyan during the launch of DepNet Armenia, 17 June 2016.
- Austrian television personality Wolfram Pirchner, at the Brain Day in Vienna, 16 September 2016.

The award has been designed to support the activities of patient groups in the area of mental health awareness and patient rights. In this it has been very successful, providing a platform for depression awareness and the visibility for local programmes and initiatives. The 2016 award, for example, was featured on the evening television by the Austrian national broadcaster ORF in its highly regarded *Heute Leben* programme.

## EUROPEAN AFFAIRS

### *Representing the field*

ECNP remains active in a variety of organisations designed to represent fundamental research, applied neuroscience and patient issues in Brussels.

- **European Brain Council (EBC)**

ECNP is a founder member of this multi-stakeholder European advocacy organisation for brain-related issues.

- **GAMIAN-Europe**

ECNP is a member of the Global Alliance of Mental Illness Advocacy Networks-Europe, which represents the interests of those affected by mental illness, advocates for their rights, and campaigned against stigma and discrimination.

- **Alliance for Biomedical Research in Europe**

ECNP is one of 24 leading biomedical societies in the Alliance, whose objectives are to promote the best interests and values of research across all medical disciplines in Europe.

## ECNP AMBASSADORS

### *Fostering integration*

The Ambassadors programme was launched in 2012 to provide representation for the College in European countries with limited access to ECNP's scientific programmes and educational opportunities. A senior neuropsychopharmacologist in his or her country, each of the 11 ambassadors helps to co-ordinate seminars and mini-symposia, to facilitate nominations to ECNP education events, and act as a point of contact for ECNP in his or her home country.

### ECNP AMBASSADORS

Armen Melik-Pashayan, Armenia

Luchozar Hranov, Bulgaria

Miro Jakovljević, Croatia

Eka Chkonia, Georgia

Elmars Rancāns, Latvia

Rok Tavcar, Slovenia

Eugenia Sinita, Moldova

Joao Bessa, Portugal

Gorica Djokic, Serbia

Oguz Karamustafalioglu, Turkey

Petr Morozov, Russia



## COMMUNICATION

### *Disseminating high-quality information*

ECNP produces and maintains a number of communication platforms to ensure evidence-based information and insights are disseminated amongst the applied neuroscience research community and to interested parties beyond.

15,000+ recipients

#### Message of the President

Every month the ECNP president sends a message to the ECNP community. Messages were sent by Guy Goodwin, and from September onwards by Celso Arango, on a range of issues and developments at ECNP level and in the field generally. The online comment section allows recipients to respond with comments of their own. On average, like the e-News, the Message of the President reaches more than 15,000 people.

15,000–17,000 recipients

#### E-News

This monthly e-news bulletin keeping the ECNP community up to date on ECNP's upcoming meetings, activities, new initiatives and developments. Sent in the first week of every month, the e-news disseminates breaking news about ECNP and its activities, including notices of recent meetings, calls for abstracts, applications for awards, a free article from European Neuropsychopharmacology, scientific highlights, and information from allied organisations in the field.

100+ FB and LinkedIn posts

#### Social Media

ECNP has been actively communicating via social media since 2012. It uses Twitter, Facebook, LinkedIn and YouTube to spread important scientific news from the field and keep followers informed throughout the year. ECNP continues to build its social media presence, in 2016 ECNP's Facebook page had over 3,600 followers, and ECNP had over a 1,000 followers on Twitter, 230 on YouTube and 250 on LinkedIn. On both Facebook and LinkedIn more than a 100 posts were placed.

There are 60+ ECNP video's on YouTube, with a 10,076 views in 2016. They were liked 93 times, and shared 110 times.



## 38,642 visits to the website

[www.ecnp.eu](http://www.ecnp.eu)

Every ECNP's internet information platform for all content related to the College and its activities received 38,642 visits in 2016, of which 83% as new versus 17% returning.


## 2,415 downloads in 2016

### ECNP app

This The ECNP app hosted all up-to-date information of the 29<sup>th</sup> ECNP Congress, as well as other ECNP meetings which took place in 2016. Through the app, ECNP also spreads the latest news about meetings and other initiatives. An interactive feature was added to the app to help meeting participants connect to each other. The feature offered the possibility to send personal messages and to chat with a group about a certain topic. The app was downloaded 2,415 times in 2016 (54% iPhone, 11% iPad, 35% Android). During the 29<sup>th</sup> ECNP Congress in Vienna there was a peak in users: 1,350 people were using the app at the same time.

### ECNP in-depth

This series of interviews with key people in the field looks at their work and what it says about the future of applied neuroscience. The interviews are published on the website and distributed by means of an e-alert and social media. The 'ECNP in-depth' series has been expanded by a number of video interviews of leading researchers about their work in the field of neuroscience and their interests. The videos are available on the ECNP website and YouTube. This initiative will be continued into 2017.



# FINANCIAL REPORT

## FINANACIAL STRATEGY

The changing environment for medical and scientific associations has been felt across all disease areas, but applied neuroscience – especially psychiatry – has been under particular pressure. The downsizing by many pharma companies of their CNS holdings or, in some cases, their exit from the area altogether has had significant consequences for a field that has historically been four-fifths funded by the industry.<sup>1</sup> This retraction of investment has been felt across the field in many ways, and has inevitably also affected the ECNP Congress.

The result has been a steady erosion of the College's income base, especially for R&S, which receives the proceeds of the ECNP Congress, if any. ECNP Association and R&S are responding with ongoing reassessments of their activities and rationalisations of their cost structures. For the next five years, however, the foundations anticipate a period of successive budgetary deficits, while programmes are reconfigured and the financial model reshaped.

In this rapidly changing landscape what constitutes relevance is also changing, as the needs and expectations of our community of members and users change and the practice of science as a discipline and career continues to evolve. As a necessary step in assuring its ongoing vitality and usefulness, the College will explore long-term investments in new kinds of services and sources of value, which will also be funded from deficit spending.

The foundations also derive income – in the case of ECNP Association, the overwhelmingly majority – from their investment portfolios. In the immediate term the market indicators are better than predicted, with a performance on the investments in 2016 significantly exceeding expectations. The extreme variability of this income – a reflection of the ongoing geopolitical uncertainty and its turbulent effects on the capital markets – presents some significant budgeting challenges for both foundations. In keeping with the conditions of their ANBI status, it is the firm policy of both foundations not to accumulate further capital.

ECNP is confident that, if it continue to be relevant to its community of users, the organisation will remain viable.

---

<sup>1</sup>P. Sobocki, 'Resource allocation to brain research in Europe (RABRE)', *European Journal of Neuroscience*, 2006 24:2691-2693.

# Financial Statements

## ECNP ASSOCIATION

### Balance sheet as at 31 December 2016 (in €)

(after appropriation of profit/losses)

	31-12-2016	31-12-2015
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
<b>Accounts Receivable</b>		
Debtors	144,494	600
Amounts owed by other foundations	190,023	412,703
Taxes	-	38,948
Other accounts receivable	<u>113,495</u>	<u>146,697</u>
	448,012	598,948
<b>Securities</b>	11,997,774	12,285,778
<b>Bank Deposits</b>	<u>2,519,445</u>	<u>1,480,423</u>
	14,965,231	14,365,149

### Equity and liabilities (in €)

	31-12-2016	31-12-2016
<b>EQUITY</b>		
Other reserves	14,852,490	14,144,987
<b>CURRENT LIABILITIES</b>		
Trade creditors	3,288	135,249
Taxes	5,215	-
Other liabilities	<u>104,238</u>	<u>84,913</u>
	112,741	220,162
	14,965,231	14,365,149

**Profit and loss account 2016 (in €)**

	31-12-2016	31-12-2015
<b>INCOME</b>		
Membership fees	68,962	51,788
Interest and similar income	1,208,696	492,747
<b>Total income</b>	<u>1,277,658</u>	<u>544,535</u>
<b>EXPENSES</b>		
Administration	180,056	208,554
Other expenses	174,822	204,609
Publication	63,817	88,513
Other activities	114,717	295,615
Interest and similar charges	36,743	37,510
<b>Total expenses</b>	<u>570,155</u>	<u>834,801</u>
<b>Net result</b>	707,503	-290,266
<b>Appropriation of result</b>		
Other reserves	707,503	-290,266

## Balance sheet as at 31 December 2016 (in €)

(after appropriation of profit/losses)

	31-12-2016	31-12-2015
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
<b>Accounts Receivable</b>		
Debtors	2,556	2,036
Amounts owed by congress foundations	209,912	409,952
Other receivables	241,095	138,939
Prepayments and accrued income	56,301	81,968
	<u>509,864</u>	<u>632,895</u>
<b>Securities</b>	8,057,509	8,400,021
<b>Bank deposits</b>	5,121,963	4,699,153
	<u>13,689,336</u>	<u>13,732,069</u>

## Equity and liabilities (in €)

	31-12-2016	31-12-2016
<b>EQUITY</b>		
Other reserves	13,374,675	13,214,593
Designated fund	55,506	200,000
	<u>13,430,181</u>	<u>13,414,593</u>
<b>CURRENT LIABILITIES</b>		
Trade creditors	148,745	46,760
Amounts owed to other foundations and college	39,134	200,964
Taxes	6,490	37,626
Other liabilities	64,786	32,126
	<u>259,155</u>	<u>317,476</u>
	<u>13,689,336</u>	<u>13,732,069</u>

**Profit and loss account 2016 (in €)**

	31-12-2016	31-12-2015
<b>INCOME</b>		
Proceeds fundraising	268,197	1,065,089
Interest and similar income	869,185	276,738
<b>Total income</b>	<u>1,137,382</u>	<u>1,341,827</u>
<b>EXPENSES</b>		
Meetings and other activities	835,671	700,145
Other expenses	286,123	282,367
<b>Total expenses</b>	<u>1,121,794</u>	<u>982,512</u>
<b>Net result</b>	15,588	359,315
 <b>Appropriation of result</b>		
Other reserves	160,082	159,315
Designated fund	-144,494	200,000
	<u>15,588</u>	<u>359,315</u>



**ECNP** *neuroscience  
applied*

#### SECRETARIAT

ECNP Office

T: +31 (0)88 75 69 555

F: +31 (0)88 75 59 900

E: [secretariat@ecnp.eu](mailto:secretariat@ecnp.eu)

[www.ecnp.eu](http://www.ecnp.eu)

#### POSTAL ADDRESS

PO Box 85410

3508 AK Utrecht

The Netherlands

#### VISITING ADDRESS

Bolognalaan 28

3584 CJ Utrecht

The Netherlands

